Abstract

Succinate Toxicity in Reperfusion Injury

Mike Murphy, Group Leader, Medical Research Council

Mitochondrial ROS have long been known to contribute to damage in conditions such as ischaemia-reperfusion (IR) injury in heart attack and stroke, but methods to stop this ROS production were limited. Over the past few years we have developed a mitochondria-targeted S-nitrosating agent, called MitoSNO, that we showed was effective in preventing ROS formation in IR injury with therapeutic implications. In addition, the protection by this compound suggested that ROS production in IR injury was mainly coming from complex I. This led us to investigate the mechanism of the ROS production and using a metabolomic approach we found that the ROS production in IR injury came from the accumulation of succinate during ischaemia that then drove mitochondrial ROS production by reverse electron transport at complex I during reperfusion. This surprising mechanism led up to develop further new therapeutic approaches to impact on the damage that mitochondrial ROS do in pathology and also to explore how mitochondrial ROS can act as redox signals.